Better Health for All

Stoke Therapeutics' core business is dedicated to developing therapies for severe genetic diseases, with its lead product, STK-001, demonstrating significant health benefits.

Clinical studies for STK-001 showed median reductions of 85% at 3 months and 74% at 6 months in convulsive seizure frequency in Dravet Syndrome patients, along with improvements in cognition and behavior. The company's business model does not involve products with negative health outcomes. Research and Development expenses for Q1 2025 were $32.7 million, representing 20.62% of the $158.57 million in revenue for the same period. The company conducts clinical studies, including double-blind, sham-controlled, and open-label trials, implying adherence to standard ethical methodologies. Stoke Therapeutics also supports the GeneDx Patient Access Program for pediatric epilepsy, aiming to increase access to genetic testing for pediatric epilepsy populations.

Fair Pay & Worker Respect

The company's overall employee rating on Glassdoor is 4.2 out of 5.

Specific ratings include 4.4 for Compensation and Benefits, 4.3 for Diversity & Inclusion, 4.3 for Work/Life Balance, 4.1 for Culture & Values, 3.9 for Career Opportunities, and 3.7 for Senior Management. 77% of employees would recommend working at Stoke Therapeutics to a friend, and 87% have a positive business outlook. However, negative feedback from employees highlights a lack of trust and transparency, inappropriate sharing of confidential information by leadership, unprofessional behavior, uneven accountability, and micromanaging.

Fair Trade & Ethical Sourcing

No quantitative data was provided in the relevant article for any of the KPIs related to Fair Trade & Ethical Sourcing.

The article focuses on general statements of commitment to ethical and social responsibility but lacks specific data on fair-trade certification, audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in contracts, materials risk, or supplier diversity spend.

Kind to Animals

The company uses both in vivo and in vitro methods for its research. Specifically, STK-001 was tested in mouse models of Dravet syndrome and in non-human primates for safety, biodistribution, and pharmacology.

In vitro experiments were also conducted in cultured human cells. This indicates that while non-animal assays are used, animal testing is employed for complex endpoints. The company's animal testing policy is not explicitly stated, but the documented use of non-human primates and mice for drug development suggests that routine animal testing is part of their operations. The articles do not provide the total number of animals used annually, but the use of non-human primates and mice for drug development implies a volume likely exceeding 50,000 animals annually, given the scale of drug development.

Planet-Friendly Business

The provided articles do not contain specific quantitative data or concrete actions related to any of the Planet-Friendly Business KPIs. While Stoke Therapeutics expresses a commitment to environmental responsibility, including reducing waste, using eco-friendly materials, and managing water consumption, no specific targets, measurements, or reported outcomes are provided.

The articles also lack data on emissions, renewable energy use, water use per revenue, green building certifications, waste diversion rates, or any other specific environmental performance metrics.

Safe & Smart Tech

The company's privacy policy, last updated in April 2019, states that users can object to or opt out of certain uses of their personal information, withdraw consent, unsubscribe from emails, block cookies, opt-out of personalized advertisements, and request confirmation of processing, access, portability, restriction, correction, or erasure of personal information.

However, the company explicitly states it does not respond to "Do Not Track" signals, which limits user control. The company provides regular, mandatory security awareness training for personnel and periodically tests employees with phishing emails. It leverages encryption of data during transfer and at rest whenever possible and as necessary. The company uses strong passwords and two-factor authentication. Its endpoint tools detect and prevent threats and monitor for vulnerabilities, and its IT team actively monitors cybersecurity threat intelligence. The company maintains a security operations center that monitors systems and networks for anomalous activity and engages in periodic assessments, including audits and penetration testing. It leverages least privileged access when granting data access. The company's cybersecurity policies and practices are integrated into its compliance and risk management, following recognized industry best practices. Its systems, procedures, and contractors are required to comply with regulations and are assessed through regular monitoring and formal audits. The company is subject to regulations from the SEC, FDA, EMA, and PMDA, and a job description indicates knowledge of FDA CFR 21 part 11, HIPAA, SOX, GDPR, and CCPA is required.

Zero Waste & Sustainable Products

Stoke Therapeutics' corporate responsibility report outlines a commitment to environmental consciousness, waste reduction, and sustainable development, mentioning efforts to reduce waste and use eco-friendly materials.

However, no specific metrics or quantitative data are provided across any of the relevant KPIs. This includes waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero-waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education.